Clinical Report: Investigating the Structure-Activity Relationships of Synthetic Cathinones
Background
Synthetic cathinones, a significant group of new psychoactive substances (NPS), pose a growing public health threat due to their increasing prevalence and limited understanding of their effects. These substances mimic the effects of traditional stimulants while evading legal restrictions, complicating efforts to manage their use and associated risks. Understanding their pharmacological profiles is crucial for developing effective public health responses.
Data Highlights
No numerical data available in the provided material.
Key Findings
α-PiHP is a potent dopamine transporter (DAT) inhibitor with a high DAT/SERT ratio.
In vivo studies indicate α-PiHP produces robust psychostimulant effects similar to cocaine and methamphetamine.
Reported human effects of α-PiHP include euphoria, tachycardia, and paranoia, as noted in recent studies.
New analogues of α-PiHP, such as 4-F-α-PiHP, have emerged, indicating ongoing structural modifications in response to regulatory actions.
α-PiHP was placed in Schedule II of the 1971 Convention on Psychotropic Substances in 2023 due to its abuse potential.
Clinical Implications
Healthcare professionals should be aware of the increasing prevalence of synthetic cathinones and their potential for severe adverse effects.
Conclusion
The emergence of α-PiHP and its analogues highlights the dynamic nature of synthetic cathinones and the need for ongoing research to understand their impact on health and safety.
by Martalu D. Pazos, Guillermo García-Díez, David Pubill, Xavier Berzosa, Roger Estrada-Tejedor, Jorge Camarasa, Elena Escubedo, Raúl López-Arnau, Núria Nadal-Gratacós
Longer initial prescriptions, use of multiple benzodiazepines, and long-acting agents were associated with delayed discontinuation in a retrospective population-based cohort study.
